carvedilol has been researched along with Hyperplasia in 2 studies
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is a direct inhibitor of vascular smooth muscle cell migration and proliferation through inhibition of mitogen-activated protein kinase activity and regulation of cell cycle progression." | 2.71 | Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. ( Cha, KS; Kim, DI; Kim, DS; Kim, HJ; Kim, JS; Kim, JW; Kim, MH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, KS | 1 |
| Kim, MH | 1 |
| Kim, JW | 1 |
| Kim, DI | 1 |
| Kim, HJ | 1 |
| Kim, DS | 1 |
| Kim, JS | 1 |
| Wu, TC | 1 |
| Chen, YH | 1 |
| Leu, HB | 1 |
| Chen, YL | 1 |
| Lin, FY | 1 |
| Lin, SJ | 1 |
| Chen, JW | 1 |
1 trial available for carvedilol and Hyperplasia
| Article | Year |
|---|---|
Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; C | 2004 |
1 other study available for carvedilol and Hyperplasia
| Article | Year |
|---|---|
Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Aorta, Abdominal; Atherosclerosis; Carbazoles; C | 2007 |